Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Vanda Pharmaceuticals Inc.

VNDA: Vanda is a commercial CNS and rare-disease portfolio trading at $4.58 and valued more like a broken story than a functioning specialty-pharma business. Fanapt, Hetlioz and the tradipitant development path offer approved or late-stage assets rather than pure discovery-stage optionality. The base case is commercial rerating; a specialty-pharma or CNS-focused buyer could provide M&A support through existing infrastructure, but an acquisition is not required. Key uncertainties are franchise durability, sales execution, regulatory and litigation exposure, and whether pipeline value requires excessive capital.

Read full article (1 min)